International Research Journal of Oncology

Breast cancer is the most common cancer diagnosed in females throughout the entire world, and it is also the primary reason why people lose their lives due to malignant tumors. The risk of developing breast cancer is increasing at an alarming rate over the whole planet. In light of this, it is essential to search for innovative therapeutic techniques in addition to predictive and prognostic indicators, notwithstanding the progress that has been made in identifying and treating the disease, which has resulted in a reduction in the overall mortality rate. Several distinct therapy modalitieutilized, each of which is determined by the molecular subtype. Systemic therapy and locoregional therapy, which include surgery and radiation therapy, are both components of the multidisciplinary strategy that is taken to treat breast cancer. Chemotherapy, anti-HER2 therapy for diseases that are positive for HER2, hormone therapy for diseases that are positive for hormones, and immunotherapy, which was developed more recently, are all examples of systemic therapies. Triple negative breast cancer accounts for between 15% and 20% of all breast cancers. This subtype of breast cancer affects more than 15% of patients. As a result of its poor response to treatment and the exceedingly invasive nature of the condition, it presents a therapeutic challenge and, as a result, generates a significant amount of research interest. The treatment of breast cancer in the future will hopefully be more individualized, with the ability to de-escalate when necessary and escalate when necessary based on the biology of the tumor as well as an early therapeutic response. This article provides an overview of the research that has been done on breast carcinoma, which is a disorder that affects women all around the world.